Table II.
Baseline (Visit 1) and Treatment (Visit 2) Vital Signs, Pulse Wave Analysis, and Biochemical Values
| Nebivolol Visit 1 | Nebivolol Visit 2 | P Value (Nebivolol) | Placebo Visit 1 | Placebo Visit 2 | P Value (Placebo) | |
|---|---|---|---|---|---|---|
| Hemodynamic traits | ||||||
| Aortic SBP, mm Hg | 112.7±2.5 | 106.2±2.4 | .011 | 107.7±1.9 | 106.6±2.0 | .629 |
| Aortic DBP, mm Hg | 79.1±2.3 | 71.3±1.9 | .009 | 75.9±1.7 | 74.0±1.8 | .312 |
| Aortic MAP, mm Hg | 94.2±2.1 | 86.8±1.9 | .002 | 90.4±1.6 | 88.6±1.9 | .314 |
| Aortic pulse pressure, mm Hg | 33.6±2.3 | 34.9±1.8 | .710 | 31.8±1.4 | 32.6±1.2 | .647 |
| Aortic augmentation pressure, mm Hg | 7.4±2.0 | 6.8±1.6 | .939 | 5.5±1.0 | 5.3±1.1 | .862 |
| Aortic augmentation index for heart rate 75, % | 14.7±3.4 | 11.9±3.8 | .415 | 14.5±2.4 | 12.8±2.9 | .534 |
| Pulse wave velocity, m/s | 6.73±0.28 | 6.00±0.18 | .088 | 5.95±0.19 | 5.78±0.19 | .441 |
| Heart rate, beats per min | 72.0±1.9 | 64.4±2.3 | .001 | 75.6±1.9 | 72.1±2.0 | .157 |
| Biochemical traits | ||||||
| Urine NO excretion, μmol/mg Cr | 40.31±5.05 | 64.38±14.25 | .030 | 61.77±11.86 | 65.54±10.54 | .710 |
| Plasma IL‐6, pg/mL | 1.626±0.598 | 1.647±0.689 | .353 | 1.351±0.258 | 1.351±0.285 | .932 |
| Urine isoprostane excretion, pg/mg Cr | 1.80±14 | 213±20 | .192 | 165±17 | 185±22 | .493 |
| Urine H2O2 excretion, μmol/mg Cr | 0.652±0.274 | 2.79±1.83 | .363 | 0.500±0.281 | 0.578±0.194 | .638 |
Abbreviations: Cr, creatinine; DBP, diastolic blood pressure; H2O2, hydrogen peroxide; IL, interleukin; MAP, mean arterial pressure; NO, nitric oxide metabolites; SBP, systolic blood pressure.
Significance of the drug effect (nebivolol or placebo); bold if P<.05.